Trinity Biotech (TRIB) - מכפיל P/S עתידי

Trinity Biotech plc develops diagnostic tests for diabetes and infections, competing through a closed equipment ecosystem. The estimated forward P/S helps objectively assess multiples, with the parameter value equal to 0.10. The business scales through regular sales of high-margin reagents. Modernized plants with high capacity utilization for diagnostic system production ensure stable profits.

High capacity utilization at Trinity Biotech plc (TRIB) for the production of test systems ensures a stable revenue stream, establishing the company as a resilient player in the diagnostics sector. The projected P/S multiple compares market capitalization with expected sales volume, allowing investors to determine the degree of overvaluation of the shares and assess the correlation between revenue growth rates and gross margin efficiency.